Additional Information
Market: AIM
Sector: Pharmaceuticals & Biotechnology
EPIC: EHP
Latest Price: 327.50p  (0,00%)
52-week High: 585.00p
52-week Low: 321.50p
Market Cap: 31.93M
1 year chart More charts
Deal EHP Tax Free*
*subject to change and depends on individual circumstances.
1 day chart More charts
Advertisement
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Epistem Holdings Plc
www.epistem.co.uk
Deal Epistem Holdings Plc Tax Free* Losses can exceed
your initial deposit
*subject to change and depends on individual circumstances.

Epistem is a biotechnology company commercialising adult stem cells in the areas of oncology and gastrointestinal diseases as well as cosmeceutical applications. Epistem develops innovative therapeutics and diagnostic biomarkers and provides contract research services to drug development companies. The Group's expertise is focused on...

Read more
Pdf

Epistem expected to sign more partners as TB test gets European approval, says broker

July 05 2012, 1:52pm Epistem received the CE-IVD registration for its rapid molecular test for tuberculosis (TB), an infectious and potentially lethal disease, which affects the lungs and causes a chronic cough.

 

---Adds broker comment and share price---

Stem cell specialist Epistem (LON:EHP) is likely to sign more partners for its Genedrive diagnostic platform, after being granted a CE mark as an in-vitro diagnostic medical device, reckons broker Peel Hunt. 

The certification means the test, which is based on its core Genedrive diagnostic platform, can now be sold across the European Economic Area (EEA).

Epistem received the CE-IVD registration for its rapid molecular test for tuberculosis (TB), an infectious and potentially lethal disease, which affects the lungs and causes a chronic cough.

Peel Hunt Analyst Dr Paul Cuddon said: “Genedrive has overcome the first key hurdle, and looks well set to continue to expand the menu, sign more commercial partners and maximise returns from a truly disruptive diagnostics innovation.”

He added that the registration also enables Epistem’s ability to broaden the range of tests across infectious diseases and cancer, where Genedrive has the technical specifications to become a “class leading technology.”

He added: “Not only is Genedrive cheaper than peers, its technical specifications are better.”

Peel Hunt gives a ‘buy’ recommendation on the stock and target price of 515 pence.

City broker Daniel Stewart agrees also giving a ‘buy’ recommendation and 496 pence target.

Epistem is now preparing regulatory submissions for India ahead of its first molecular TB test including patient assessment for antibiotic resistance towards the end of this year.

India has the largest number of TB sufferers in the world with more than two million new cases each year.

Dr Cuddon said: “A low cost, fast point of care molecular test has the potential to make a significant commercial and clinical impact through breaking the chain of disease transmission in rural areas.”

Matthew Walls, Epistem’s chief executive said: "This is an important milestone for the company as we move towards our first significant revenue stream in the commercialisation of Genedrive."

The CE-IVD mark is the first successful registration of a test using Genedrive.

The Genedrive platform provides a 'Point of Care' test applicable to a wide range of viral, bacterial, fungal and somatic mutation disease areas in less than thirty minutes.

Genedrive will be targeted at providing 'gold standard' identification of Mycobacterium tuberculosis and antibiotic resistance testing and will be priced competitively, Epistem added. 

In addition to its Genedrive platform Epistem also works in the discovery and development of biomarkers, which are used to monitor the progress of drug treatments.

The share price was up 1 per cent to 404 pence.

 

 

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.